» Articles » PMID: 35122713

Methods and Indicators to Validate Country Reductions in Incidence of Hepatitis C Virus Infection to Elimination Levels Set by WHO

Abstract

One of the main goals of the 2016 Global Health Sector Strategy on viral hepatitis is the elimination of hepatitis C virus (HCV) as a public health problem by 2030, defined as an 80% reduction in incidence and 65% reduction in mortality relative to 2015. Although monitoring HCV incidence is key to validating HCV elimination, use of the gold-standard method, which involves prospective HCV retesting of people at risk, can be prohibitively resource-intensive. Additionally, few countries collected quality data in 2015 to enable an 80% decrease by 2030 to be calculated. Here, we first review different methods of monitoring HCV incidence and discuss their resource implications and applicability to various populations. Second, using mathematical models developed for various global settings, we assess whether trends in HCV chronic prevalence or HCV antibody prevalence or scale-up levels for HCV testing, treatment, and preventative interventions can be used as reliable alternative indicators to validate the HCV incidence target. Third, we discuss the advantages and disadvantages of an absolute HCV incidence target and suggest a suitable threshold. Finally, we propose three options that countries can use to validate the HCV incidence target, depending on the available surveillance infrastructure.

Citing Articles

Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention Strategies.

Cheema J, Suckow S, Ramers C, Loose P, Tomada A, Tweeten S Viruses. 2025; 16(12.

PMID: 39772129 PMC: 11680419. DOI: 10.3390/v16121819.


Monitoring Progress Towards the Elimination of Hepatitis C as a Public Health Threat in Norway: A Modelling Study Among People Who Inject Drugs and Immigrants.

Whittaker R, Midtbo J, Klovstad H J Infect Dis. 2024; 230(3):e700-e711.

PMID: 38537267 PMC: 11420790. DOI: 10.1093/infdis/jiae147.


In search of a 'good number': knowledge controversy and population estimates in the endgame of hepatitis C elimination.

Rhodes T, Lancaster K, Adams S BMJ Glob Health. 2024; 9(2).

PMID: 38413104 PMC: 10900359. DOI: 10.1136/bmjgh-2023-014659.


Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015.

Walker J, Tskhomelidze I, Shadaker S, Tsereteli M, Handanagic S, Armstrong P Euro Surveill. 2023; 28(30).

PMID: 37498534 PMC: 10375834. DOI: 10.2807/1560-7917.ES.2023.28.30.2200952.


Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.

Artenie A, Stone J, Facente S, Fraser H, Hecht J, Rhodes P J Infect Dis. 2023; 228(6):662-673.

PMID: 37486337 PMC: 10503949. DOI: 10.1093/infdis/jiad169.


References
1.
Kouyoumjian S, Chemaitelly H, Abu-Raddad L . Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018; 8(1):1661. PMC: 5785953. DOI: 10.1038/s41598-017-17936-4. View

2.
Walker J, Kuchuloria T, Sergeenko D, Fraser H, Lim A, Shadaker S . Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health. 2019; 8(2):e244-e253. PMC: 7025283. DOI: 10.1016/S2214-109X(19)30483-8. View

3.
Averhoff F, Lazarus J, Sergeenko D, Colombo M, Gamkrelidze A, Tsertsvadze T . Excellence in viral hepatitis elimination - Lessons from Georgia. J Hepatol. 2019; 71(4):645-647. DOI: 10.1016/j.jhep.2019.06.026. View

4.
Tsertsvadze T, Sharvadze L, Chkhartishvili N, Dzigua L, Karchava M, Gatserelia L . The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia. Virol J. 2016; 13:22. PMC: 4739321. DOI: 10.1186/s12985-016-0478-6. View

5.
Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen K . Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014; 9(7):e103345. PMC: 4113410. DOI: 10.1371/journal.pone.0103345. View